The stock of Premaitha Health PLC (LON:NIPT) gapped up by GBX 0.125 today and has GBX 8.84 target or 6.00% above today’s GBX 8.34 share price. The 6 months technical chart setup indicates low risk for the GBX 19.31 million company. The gap was reported on Nov, 22 by Barchart.com. If the GBX 8.84 price target is reached, the company will be worth GBX 1.16M more.
Gaps up are useful for using as a support level and to some extent as a tradeable event. If investors already hold the stock and experience a price gap up, then its usually a good idea to hold the stock for a stronger up move. Back-tests of these patterns indicate that two-thirds of the times the stock performance improves after the gap. The area gaps close 89% of the time, the breakaway gaps, 2%, the continuation gaps 4% and the exhaustion gaps 61%. The stock decreased 4.74% or GBX 0.41 on November 22, hitting GBX 8.34. About 732,529 shares traded hands or 11.89% up from the average. Premaitha Health PLC (LON:NIPT) has declined 11.39% since April 22, 2016 and is downtrending. It has underperformed by 15.95% the S&P500.
Premaitha Health PLC (LON:NIPT) Ratings Coverage
Out of 2 analysts covering Premaitha Health Plc (LON:NIPT), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Premaitha Health Plc has been the topic of 28 analyst reports since September 22, 2015 according to StockzIntelligence Inc. Panmure Gordon maintained the shares of NIPT in a report on Wednesday, October 14 with “Buy” rating. The firm earned “Corporate” rating on Tuesday, August 30 by FinnCap. Panmure Gordon maintained the shares of NIPT in a report on Wednesday, January 27 with “Buy” rating. Panmure Gordon maintained it with “Buy” rating and GBX 24 target price in Tuesday, February 2 report. On Monday, October 12 the stock rating was maintained by Panmure Gordon with “Buy”. FinnCap maintained Premaitha Health PLC (LON:NIPT) rating on Monday, October 31. FinnCap has “Corporate” rating and GBX 20 price target. The rating was maintained by FinnCap with “Corporate” on Monday, July 4. FinnCap maintained it with “Corporate” rating and GBX 20 target price in Friday, September 30 report. The company was maintained on Thursday, November 12 by Panmure Gordon. The firm has “Corporate” rating by FinnCap given on Monday, April 11.
More news for Premaitha Health PLC (LON:NIPT) were recently published by: Businesswire.com, which released: “Premaitha Health PLC Premaitha Health signs Investment Agreement with Thermo …” on December 14, 2015. Uk.Finance.Yahoo.com‘s article titled: “Premaitha Health PLC (NIPT.L)” and published on July 07, 2014 is yet another important article.
Premaitha Health PLC is engaged in molecular diagnostics business for research into, and the development and commercialization of gene analysis techniques for pre-natal screening and other clinical applications in the early detection, monitoring and treatment of disease. The company has a market cap of 19.31 million GBP. The Company’s product, the IONA test is a non-invasive in vitro diagnostic product for prenatal screening enabling clinical laboratories to offer a regulated non-invasive prenatal test in-house. It currently has negative earnings. The IONA test estimates the risk of a fetus having Down’s syndrome or other serious genetic diseases.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.